Get the Stockscreener App
1.30
2.36%
0.03
After Hours:
1.32
0.02
+1.54%
Pacific Biosciences Of California Inc stock is traded at $1.30, with a volume of 3.72M.
It is up +2.36% in the last 24 hours and up +14.04% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
See More
Previous Close:
$1.27
Open:
$1.29
24h Volume:
3.72M
Relative Volume:
0.58
Market Cap:
$404.08M
Revenue:
$160.03M
Net Income/Loss:
$-128.58M
P/E Ratio:
-3.0459
EPS:
-0.4268
Net Cash Flow:
$-121.21M
1W Performance:
-3.70%
1M Performance:
+14.04%
6M Performance:
-3.70%
1Y Performance:
+3.17%
1-Day Range:
$1.28
$1.32
1-Week Range:
$1.25
$1.36
52-Week Range:
$1.07
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.30 | 394.76M | 160.03M | -128.58M | -121.21M | -0.4268 |
ABT
Abbott Laboratories
|
101.95 | 178.85B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
90.96 | 117.19B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.56 | 103.57B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.98 | 62.46B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
84.37 | 50.01B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating - Moomoo
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know - Yahoo Finance
How to build a more competitive grant proposal without losing your research time to it - PacBio
Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue? - Eastern Progress
PacBio to Participate in the Morgan Stanley 24?? Annual Global Healthcare Conference - marketscreener.com
PACB stock gains as PacBio highlights sequencing strength ahead Morgan Stanley conference - ad-hoc-news.de
PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference - marketscreener.com
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead? - TradingView
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test - TradingView
3 Reasons to Sell PACB and 1 Stock to Buy Instead - Yahoo Finance
Pacific Biosciences (PACB) Tumbles 9.7% to $1.40, Nears Critical Support at $1.33Stock News - vinanet.vn
Pacific Biosciences of California (PACB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
PACB Stock Pops As New CEO Backs Powerful Vega Upgrade - StocksToTrade
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
Pacific (PACB) Earnings Update: EPS Misses Its Estimate on the Day; Trading Response: Shares Close 11.40% Higher in Latest TradingEarnings Weakness Phase - Vinanet
Pacific Biosciences CEO Mark van Oene sells $30,409 in stock By Investing.com - Investing.com South Africa
Pacific Biosciences of California (PACB) Institutional Ownership 2026 - MarketBeat
Pacific Biosciences CEO Mark van Oene sells $30,409 in stock - Investing.com
Insider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells 26,911 Shares of Stock - MarketBeat
PacBio (NASDAQ: PACB) CEO share sale covers RSU tax withholding - Stock Titan
Pacific Biosciences of California Inc (HAM:P09) Stock Price, Trades & News - GuruFocus
Pacific Biosciences of California Inc (PACB) (Q2 2026) Earnings - GuruFocus
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SEC Filing (Aug 17, 2026) - Stock Titan
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity - MarketBeat
ARK reports 9.59% stake in Pacific Biosciences (PACB) - Stock Titan
5 Must-Read Analyst Questions From PacBio’s Q2 Earnings Call - Yahoo Finance
PACIFIC BIOSCIENCES (PACB) CEO granted 1.97M options and 489K RSUs - Stock Titan
Measuring – not guessing – the true path - PacBio
Weekly Recap: PACB cuts 2026 revenue guide and Mark Van Oene named CEO - TradingView
Pacific Biosciences of California, Inc. $PACB Shares Sold by Renaissance Technologies LLC - MarketBeat
Pacific Biosciences of California, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PACB) 2026-08-08 - Seeking Alpha
Earnings Release: Here's Why Analysts Cut Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Price Target To US$2.29 - simplywall.st
Pacific Biosciences of California (NASDAQ:PACB) Cut to "Sell" at Wall Street Zen - MarketBeat
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2026: Revenue $39.01M, EPS ($0.14) — 10-Q Summary - TradingView
Pacific Biosciences of California, Inc. Stock 12‑Month Price Target Cut to $2.29, Implies 76% Upside - TradingView
TD Cowen Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3 - Moomoo
PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut - Yahoo Finance
Pacific Biosciences: It's Only Getting Worse (NASDAQ:PACB) - Seeking Alpha
Pacific Biosciences of California Q2 Earnings Call Highlights - TradingView
Pacific Biosciences of California, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Pacific Biosciences of California Appoints New CEO, Plans to Cut 8% of Workforce - Moomoo
Pacific Biosciences of California (PACB) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
PacBio Q2 2026 slides: SPRQ-Nx launch amid revenue miss, cut guidance - Investing.com
Is Pacific Biosciences (PACB) Positioned for Growth After Q2 Ear - GuruFocus
PacBio (NASDAQ:PACB) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings - Barchart.com
Pacific Biosciences of CaliforniaEstimates - Moomoo
PacBio names Mark Van Oene as CEO, replacing Christian Henry By Investing.com - Investing.com South Africa
PACIFIC BIOSCIENCES OF CALIFORNIACHRISTIAN HENRY STEPS DOWN AS PRESIDENT AND CEO - moomoo.com
PacBio Appoints Mark Van Oene as President and Chief Executive Officer - The Manila Times
Pacbio Appoints Mark Van Oene as President an - Moomoo
Pacific Biosciences Announces Restructuring Plan, Cutting 8% of Workforce to Drive Up to $40 Million in Annual Savings by 2027 - marketscreener.com
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):